Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis

Zamami et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d968a394760e72e6a3c5da — DOI: https://doi.org/10.1001/jamaoncol.2019.3113

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Fulminant Myocarditis with Combination Immune Checkpoint Blockade· 2016 · 2,246 citations
2. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab· 2016 · 817 citations
3. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood· 2013 · 126 citations
4. Sex differences in tolerability to Anti-PD1 therapy: Are we all equal?· 2018 · 2 citations
5. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study· 2018 · 1,180 citations